Nasus Pharma Stock Forecast
NYSE: NSRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 3:59 PM ET · Delayed 15 min
NSRX analyst consensus
Consensus (2 analysts)
buy
Avg. price target
$19.67+460.40%
- Strong buy 2
- Buy 0
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 2 Wall Street analysts covering Nasus Pharma (2026-10-09), 2 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $19.67, with a high estimate of $22.00 and a low estimate of $18.00. The average target implies upside of 460.4% from the current price of $3.51.
The spread between the highest and lowest targets is 22.2%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for NSRX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 100% |
| Buy | 0 | 0% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $18.00 | +412.82% |
| Average target | $19.67 | +460.40% |
| High target | $22.00 | +526.78% |